Unclassified · Medical Literature

[Articles] Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study

Authors
Vallerie V McLaughlin, Derek Solum, Daniel Lachant, Ali Ataya, Joan A Barberà, Gisela Bohns Meyer, Sung-A Chang, Richard Channick, Colin Church, John Feenstra, Sean Gaine, George Giannakoulas, Carlos Jerjes-Sanchez, Dinesh Khanna, Nick H Kim, Ronald Oudiz, Ioana R Preston, Namita Sood, Fernando Torres, Jean-Luc Vachiery, Tomás Pulido, Dana Cella, Chunqin Deng, Miluska Escudero, Victoria Lacasse, Leigh Peterson, Raymond Benza, Marc Humbert, ADVANCE OUTCOMES Investigators
Journal
The Lancet
Publication date
2026-07-28
Source
rss_lancet
Original record ID
210172
Summary status
error
Analysis status
error
Original last updated
2026-08-10T06:56:08.000Z

Open original source

Abstract

In patients with PAH receiving contemporary background therapy, ralinepag significantly reduced the risk of first clinical worsening compared with placebo, but was associated with more adverse-event-related treatment discontinuations. These results support the use of ralinepag as an oral, once-daily prostacyclin-pathway treatment option for PAH.